logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn reveals more promising results from its clinical trials in breast cancer

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company has revealed additional “promising results” from its clinical trials evaluating its lead drug leronlimab for the treatment of metastatic triple-negative breast cancer and metastatic breast cancer. Pourhassan says the company is hopeful the latest result will be added to its Breakthrough Therapy Designation application for the drug.

Quick facts: CytoDyn Inc.

Price: 3.1 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.49 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Duke Royalty Limited 'doing just fine' by maintaining a diversified...

Duke Royalty Limited (LON:DUKE) CEO Neil Johnson tells Proactive the provider of alternative capital solutions is 'doing just fine' and withstanding the current pandemic situation by maintaining a diversified portfolio. Johnson says Duke, which recently reported a trading update, has exposure...

3 days, 12 hours ago

2 min read